FDA grants approval of idecabtagene vicleucel for treatment of adults with relapsed/refractory multiple myeloma
Approval of this first in class B-cell maturation antigen therapy is based on a study of 127 pts who received at least three prior lines of therapy. The overall response rate was 72% and 28% achieved a complete response, of which 65% had remission lasting at least 12 months.
Source:
US Food and Drug Administration